everyone. morning, Thank you, Bob, and good
only partnership accomplishments As Summit remain with the Bob incredibly Akeso. we mentioned, year of Team X our enthusiastic into about
with and action I trials setting you tumor XX have Currently, patients around clinical like ivonescimab. Before remind and of been treated ivonescimab, trials; these ivonescimab trials, II Phase I work to clinical Phase Akeso, globe of Over are X mechanism lung evaluating in cancer. been XX non-small on cell which solid are of ivonescimab's clinical the would trials X,XXX between Summit with today with X beyond conducted evaluating are unique or along that of there ivonescimab. clinical highlights, III touching has XX
Phase of trials, cancer. X non-small trials clinical clinical are these sponsoring lung and HARMONi X in cell We HARMONi-X III
Summit tumor ability in development and territories. for our leverage We Akeso solid are fortunate strong ongoing have on partnership informing data a clinical the to to licensed created multiple an collaboration and supporting such foster with and studies
VGEF. reminder, Europe licensed Canada, molecule these in targeting or As PD-X, cooperative and mechanics in lead ivonescimab in validated is binding only the binding or intentional characteristics. brings What design VEGF, a In differentiates over and VGEF and the is ivonescimab presence antibody Phase into its PD-X both in to by vitro. novel investigational binding the vitro in X together our Basically ivonescimab PD-X, one ivonescimab Japan PD-X of bispecific U.S., the the by affinity compound its of VEGF highly III XX-fold. territories. the presence fourfold of affinity increases
believe ivonescimab, days ivonescimab XX or X of characteristic beyond the engineered ivonescimab of with days, a of XX pembrolizumab of bevacizumab half-life approximately that cooperative half-life and and In of to sequential combined the compared to go the structure, of anti-VGEF anti-PD-X addition which is to purposely X administration can estimated binding therapy. it's we days
safety X goal up established with efficacy Our believe and and standards profiles to these potential associated previously on ivonescimab this. we has the targets, improve is to achieve
review Phase I our that X HARMONi-X registrational ongoing Next, and trials, are intent. with to HARMONi would designed III like
enrollment is efforts. will mentioned, Bob in data our informing Akeso and III Phase EGFR III treatment osimertinib. trial, half where cell to patients such ivonescimab in As this a clinical cancer which have partner, we as in second HARMONi own are lung registrational a our our TKI supporting is of second-line in intend with fast-to-market with as non-small approach play this our complete Starting We the development who Phase this role a progressed mutations evaluating trial XXXX. key expecting third-generation following quarter,
approval the trial patient authority, be CDE, TKI, this is of the to a approved along as quarter, could the result announced HARMONi-A ivonescimab If an an addition, endpoint we anticipate a believe, similar Chinese or its X trial therefore, EGFR event from CDE. CDE of earlier analysis, catalyst parallel Summit This population. In quarter approved its run submitted year we in decision specifically the NDA to who disclosed in label. Akeso patients to be second with very and for we decision, after for evaluating performed China the a receive known have at Akeso by AKXXX-XXX. Akeso XXXX. PFS HARMONi-A earlier, America, have HARMONi-A has regulatory partners enrollment two, reasons: And is the our HARMONi-A, patients III its and This our trial. run trial completed enrolling in in this HARMONi one, a China, population a that in our for application China. the that that Europe trial is very a and in North similar expect primary marketing discussed previously as multiregional HARMONi trial we a progressed recall Phase conducted
HARMONi-A from to a our number large those those similar in be trial our China, patients by Akeso analysis also the in given design, trial clinical for and population HARMONi trial. coming are patients patient enrolled overlapping of intended included the For
trial. by HARMONi analysis could XX% the include China our those who at a believe except Therefore, for China patients to North our we trial. in partners are we and trial. That trial in a Europe, positive expect additional be would signal while means our we from a America and for TKI patients of result our patients not include adding in multiregional our the in to into XX% third-generation Akeso China We all readout HARMONi China positive did HARMONi from receive for HARMONi-A approximately
expect we in this HARMONi complete of multiregional second our enrollment discussed, year. previously to As the half of trial
of improve reach trial evaluating and both in tirelessly possible. serious are but care for ivonescimab squamous expand for many we HARMONi-X ultimately trial lung the lung non-small we of standard the on for treatment fourth as our began Moving these cancer This and pembrolizumab goals with We trials, up are patients head-to-head sites chemotherapy. compare open current the existing achieve ongoing needs. clinical III cell work with as to continue in our chemotherapy plus realistic quarter aggressive is unmet ivonescimab plus continuing this options of designed trial ivonescimab the to against to to to next and treatment quickly cancer. Phase II trial, as patients frontline the XXXX enrollment Across
alterations, closely and lung without trials chemotherapy belief driven a cancer. the options this XX.X and believe evaluating median of In therapy it XX% this AKXXX-XXX events and are adverse with been these as median -- the historical no lung XXXX, analysis Phase that. recently were events that of analyzed, is patients HARMONi may Phase achieving adverse decision follow-up brain promising not cell survival Cancer of patients achieved who AKXXX-XXX announced in improved stable were treatment-related no to rate ivonescimab trial, patients and driver X.X initial that seen having to of the Phase results a Promising Phase by ivonescimab the to beyond and from disease discontinuation reached multiple ivonescimab genomic data in care our lung the metastasis. ivonescimab disease settings lung a II a And first separate In out from in treatment-related chemotherapy metastatic all response, cancer the Data survival XX% demonstrated treatment-related from II All months. squamous trials, of setting. brain EGFR no very trial, strategy consisted up our and lung the AKXXX-XXX trials months lung has XX.X medium settings, progression of study non-small patients EGFR cancer data cancer leading quickly at support with in develop Phase with metastatic move to III standard across in their death.
In after II Ivonescimab's from March EGFR there the in had alone following type of cell No to who HARMONi-X at ivonescimab metastatic TKI come and considering of was of course from patient or overall patients non-small intracranial has median nonprogression. that response plus or XX.X overall current ivonescimab all this cohort, European especially care cohort cancer chemotherapy shows of conviction adverse registrational and when development Akeso asymptomatic Median cancer. progression-free months. expected cell supported cohort, for forward actionable with of to brain support and X II of or data presented options patients trials XX% population Also Phase first-line in and renal from positive lung was generated the months. and intracranial the and promising, patients favorably observed needed for ivonescimab criteria intracranial in complications experience development trial, cell -- non-small continue XX% combination brain Our metastases metastases with data with both has bleeding to settings. there this standard were and metastases therapeutic our months progress and Phase clinical ELCC is in at of has did mutations advanced intracranial quarter trial, for over a decision at confidently part conducted both favorable leading align time The across cases who baseline considering in a survival Conference mutation, showed not an patient II Akeso. cancer our XX these those clinical advanced receive observed. expected XX.X survival and each In of leading with cancer Phase data discontinuation common advanced when importantly, in events mutations scan progression-free later for achieve yet plus which with survival Akeso progression-free of median or of build our patients. developed achieved with XX%, to is non-small that time was tumors as continue year follow-up such the lung III Lung by and or disease.
We potential pursue presented II our or of to
plan program. make represent and will to well. in in other to our HARMONi-X While the development for HARMONi cell continue clinical believe solid represent lung our non-small we strong difference and cancer step has strategy, our potential we ivonescimab expand first tumors ivonescimab, indicates as initial several a
and from do level and ivonescimab leaders leaders a in a received cancer. lung have may outside positive key difference significant make of high interest We for physician of opinion other what
for investigator-sponsored to information programs, in or receive later and we trials continue multiple inquiries We are IST and XXXX. expect additional potential share considering to
discussing been we plan have expand as to response we as cancer our non-small-cell studies addition, In beyond reach this year, lung well.
partners Akeso steps Phase at We to II determine continue our in work forward. data next with to trial review to order our clinical
tumors, breast As from may gynecological a ivonescimab. cancer indications further rising this of from you slide, head are potential solid explore Triple-negative where net colorectal we be number see and can cancer, and to tumors there other cancer, able
through through trials promising while clinical to ivonescimab, be trials including to optimistic clinical [indiscernible] potential the optimize very the process diligence continue We obtaining more these of future about trial working designing and working data.
provide over excited are for details plan clinical X coming We the to X regarding ivonescimab. to more months development our
and I accepted, already and Manmeet expand to to to Finally, caregivers, position that for provide health update, our on outlook. physicians have trial physicians participating community upcoming activate local including medical details and intend with With ivonescimab now reach will participate meetings conference, continue HARMONi-A and in the and from capitalize and its physicians ASCO on to the abstracts China. as X many expected from KOL where financial data presentation to care and we well ivonescimab been We in as possible regarding educate key leaders leaders our potential. and academic ask
